Immatics

Immatics ROA

The Return on Assets (ROA) of Immatics (IMTX) as of Nov 20, 2026 is -34.93 %. In the previous year, Return on Assets (ROA) was 2.19 % — a change of -1,698.05% (lower).

ROA

-34.93 %

YoY

-1,698.05%

Last updated:

In 2025, Immatics's return on assets (ROA) was -34.93 %, a -1,698.05% increase from the 2.19 % ROA in the previous year.

The Immatics ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
-23.51 EUR
Jan 1, 2020
-89.95 EUR
Jan 1, 2021
-53.44 EUR
Jan 1, 2022
9.20 EUR
Jan 1, 2023
-18.56 EUR
Jan 1, 2024
2.19 EUR
Jan 1, 2025
-34.93 EUR
The Immatics ROA history
YEARROAYoY
-34.93 %-1,698.05%
2.19 %-111.78%
-18.56 %-301.77%
9.20 %-117.21%
-53.44 %-40.59%
-89.95 %+282.58%
-23.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immatics Stock analysis

What does Immatics do? Immatics NV develops T cell receptor-based immunotherapies for cancer treatment, focusing on solid tumors through Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). The company's pipeline includes eight therapeutic programs, with four in clinical trials: IMA201 (MAGEA4/8), IMA202 (MAGEA1), ACTolog IMA 101 (Multi-target pilot trial), and IMA203 (PRAME). Four programs are in preclinical development, such as IMA204 (COL6A3) and IMA401 (Cancer testis antigen). Immatics generates revenue through licensing agreements and potential future sales of its therapies, targeting pharmaceutical companies and research institutions seeking advanced cancer treatments. The company's clinical-stage therapies are designed to enable robust T-cell responses against cancer targets, with programs like IMA201 and IMA202 focused on solid tumors. IMA203 addresses both hematological and solid cancers, while preclinical programs like IMA401 and IMA402 target cancer testis antigens. Immatics partners with biopharmaceutical firms to advance its pipeline, leveraging its TCR technology platform to develop therapies for unmet medical needs in oncology. Immatics' revenue model relies on strategic partnerships and licensing deals with pharmaceutical companies, which fund clinical development and gain access to its proprietary TCR platform. The firm's focus on solid tumors and hematological cancers attracts interest from major biopharmaceutical players looking to expand their oncology portfolios. Through its eight therapeutic programs, Immatics aims to deliver innovative treatments that address high unmet medical needs in cancer therapy. Immatics is one of the most popular companies on Eulerpool.

ROA Details

Understanding Immatics's Return on Assets (ROA)

Immatics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Immatics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Immatics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Immatics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Immatics stock

Return on Assets (ROA) of Immatics is -34.93 % in 2025.

Return on Assets (ROA) of Immatics changed from 2.19 % to -34.93 %, representing a -1,698.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Immatics since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Immatics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Immatics

All Key Metrics — Immatics